Table 2:
Association between transplant status and cancer-specific mortality
| Cancer site, and transplant status | Cancer-specific deaths | Cancer-specific mortality rate* | HR | 95%CI | aHR | 95%CI |
|---|---|---|---|---|---|---|
| Oral cavity/pharynx | ||||||
| Recipient | 207 | 77.1 | 0.87 | (0.76, 1.00) | 1.21 | (1.06, 1.39) |
| Non-recipient | 75,916 | 78.0 | 1 | referent | 1 | referent |
| Colorectum | ||||||
| Recipient | 369 | 132.4 | 1.38 | (1.25, 1.53) | 1.77 | (1.6, 1.96) |
| Non-recipient | 372,567 | 76.5 | 1 | referent | 1 | referent |
| Esophagus | ||||||
| Recipient | 87 | 416.3 | 0.81 | (0.66, 1.00) | 1.10 | (0.89, 1.36) |
| Non-recipient | 65,094 | 439.9 | 1 | referent | 1 | referent |
| Stomach | ||||||
| Recipient | 160 | 497.4 | 1.25 | (1.07, 1.46) | 1.47 | (1.26, 1.71) |
| Non-recipient | 102,930 | 301.0 | 1 | referent | 1 | Referent |
| Liver | ||||||
| Recipient | 118 | 392.1 | 0.74 | (0.62, 0.89) | 0.81 | (0.68, 0.97) |
| Non-recipient | 63,953 | 606.1 | 1 | referent | 1 | Referent |
| Pancreas | ||||||
| Recipient | 195 | 1165.9 | 1.24 | (1.08, 1.43) | 1.46 | (1.27, 1.68) |
| Non-recipient | 164,347 | 900.6 | 1 | referent | 1 | Referent |
| Larynx | ||||||
| Recipient | 51 | 101.5 | 1.14 | (0.87, 1.50) | 1.24 | (0.94, 1.63) |
| Non-recipient | 29,927 | 69.8 | 1 | referent | 1 | Referent |
| Lung | ||||||
| Recipient | 1,355 | 537.6 | 1.08 | (1.03, 1.14) | 1.35 | (1.29, 1.43) |
| Non-recipient | 870,934 | 424.9 | 1 | referent | 1 | Referent |
| Melanoma | ||||||
| Recipient | 152 | 73.3 | 2.54 | (2.17, 2.98) | 2.59 | (2.18, 3.00) |
| Non-recipient | 47,660 | 22.6 | 1 | referent | 1 | Referent |
| Breast | ||||||
| Recipient | 162 | 46.8 | 1.56 | (1.34, 1.82) | 1.88 | (1.61, 2.19) |
| Non-recipient | 265,229 | 27.0 | 1 | referent | 1 | Referent |
| Prostate | ||||||
| Recipient | 101 | 14.4 | 0.71 | (0.58, 0.86) | 1.07 | (0.88, 1.30) |
| Non-recipient | 188,303 | 20.4 | 1 | referent | 1 | Referent |
| Bladder | ||||||
| Recipient | 152 | 158.6 | 1.86 | (1.58, 2.18) | 1.85 | (1.58, 2.17) |
| Non-recipient | 75,981 | 61.7 | 1 | referent | 1 | Referent |
| Kidney | ||||||
| Recipient | 284 | 54.3 | 0.66 | (0.59, 0.75) | 1.23 | (1.09, 1.38) |
| Non-recipient | 71,838 | 68.4 | 1 | referent | 1 | Referent |
| Thyroid | ||||||
| Recipient | 14 | 7.8 | 0.85 | (0.50, 1.44) | 1.42 | (0.84, 2.39) |
| Non-recipient | 9,350 | 8.0 | 1 | referent | 1 | Referent |
| DLBCL | ||||||
| Recipient | 449 | 112.4 | 0.92 | (0.84, 1.01) | 1.31 | (1.20, 1.44) |
| Non-recipient | 56,983 | 108.8 | 1 | referent | 1 | Referent |
| Myeloma | ||||||
| Recipient | 74 | 129.8 | 0.73 | (0.58, 0.92) | 1.11 | (0.88, 1.39) |
| Non-recipient | 61,262 | 178.5 | 1 | referent | 1 | referent |
Abbreviations: HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; DLBCL, diffuse large B-cell lymphoma
*
Mortality rate per 1000 person-years.
† Cox regression models were adjusted for sex, age (<40,40–84 in 5 year increments,85+), race (white,black,other), stage (local,regional,distant,unknown), and diagnosis year (1987–1991,1992–1996,1997–2001,2002–2005,2006–2009, 2010–2014).